Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...

Deutsche Bank lowered the firm’s price target on Galapagos (GLPG) to EUR 22 from EUR 28 and keeps a Hold rating on the shares.Discover the Best ...

CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital. Pursuant to Belgian ...

Galapagos NV (GLPG) reports strong financials and strategic advancements amid increased R&D expenses and operational ...

CEO Paul Stoffels highlighted 2024 as a pivotal year for Galapagos, emphasizing the FDA IND clearance for GLPG5101 and strong results from the ATALANTA study in non-Hodgkin lymphoma. He outlined the ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

NEW YORK – Galapagos said on Monday that it has partnered with NecstGen, a contract development and manufacturing organization (CDMO), to support decentralized manufacturing of Galapagos' cell therapy ...

NecstGen Clean Cleanroom for CAR-T Production NecstGen, a leading Contract Development and Manufacturing Organization (CDMO) dedicated to C ...